Physician profile
Christopher Brown
NPI 1285650234
$6,100.65
in general payments reported to CMS, 2019-2025
26 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,057 · 2020: $309 · 2021: $310 · 2022: $904 · 2023: $866 · 2024: $1,175 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,504 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,504.08 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,382.50 | 2019-2025 | Rocklatan, Clareon Panoptix Pro, Clareon |
| Sun Pharmaceutical Industries INC. | $804.24 | 2019-2025 | Cequa |
| Allergan, INC. | $516.52 | 2019-2021 | |
| Abbvie INC. | $469.24 | 2022-2025 | Durysta, Lumigan, Vuity |
| Tarsus Pharmaceuticals, INC. | $403.11 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $315.59 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Ocular Therapeutix, INC. | $246.75 | 2022-2025 | Dextenza |
| Rxsight INC | $227.20 | 2024-2025 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Harrow Eye, LLC | $223.45 | 2024-2025 | Vevye |
| Glaukos Corporation | $219.65 | 2023-2025 | Idosetr |
| Johnson & Johnson Surgical Vision, INC. | $182.65 | 2019-2024 | Tecnis Simplicity, Tecnis Iol |
| Biotissue Holdings INC. | $155.30 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $143.83 | 2019-2022 | |
| Oyster Point Pharma, INC. | $132.71 | 2022-2025 | Tyrvaya, Ryzumvi |
| Ivantis, INC | $128.85 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $122.76 | 2019-2021 | |
| Dompe US, INC. | $107.63 | 2023 | Oxervate |
| Aerie Pharmaceuticals, INC. | $83.99 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $54.63 | 2019-2021 | |
| Sight Sciences, INC. | $40.79 | 2022 | |
| Mallinckrodt Hospital Products INC. | $38.54 | 2025 | Acthar |
| Shire North American Group INC | $29.06 | 2019 | |
| Amgen INC. | $21.72 | 2024 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $17.30 | 2019 | |
| Omeros Corporation | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.